Acurx Pharmaceuticals, Inc.
ACXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736243
No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Acurx Pharmaceuticals, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 11 | 9 | −2 |
| Shares | 103.5K | 348.1K | +244.6K (+236.4%) |
| Value | $455.3K | $1.15M | +$690.0K (+151.5%) |
New holders (3)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Draper Asset Management, LLC | 266,025 | $873.0K | 0.73% |
| Geode Capital Management, LLC | 10,941 | $35.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 3,319 | $11.0K | 0.00% |
Sold out (5)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| HRT Financial LP | 14,369 | $62.0K |
| Millennium Management LLC | 13,949 | $61.0K |
| Advisor Group Holdings, Inc. | 5,000 | $22.0K |
| Bank of America Corp | 104 | $0 |
| Morgan Stanley | 3 | $0 |